The clinical significance of p53 aberrations in human tumours

Virchows Archiv

Volumn 427, Issue 3, 1995, Pages 229-241

  Bosari, S ^a   Viale, G ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Human tumours; Immunohistochemistry; p53

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ADJUVANT THERAPY; APOPTOSIS; BREAST CANCER; CANCER GENETICS; DIGESTIVE SYSTEM CANCER; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT CANCER;

CHROMOSOME ABERRATIONS; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASMS; PROTEIN P53;

EID: 0028841050     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/BF00203389     Document Type: Review

References (158)

1. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions
2. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer
3. Prognostic significance of TP53 in breast carcinoma
4. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms
5. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?
6. p53: Fifteen years after discovery
7. Prognostic value of p53 overexpression and c-Ki- ras mutations in colorectal cancer
8. Prognostic significance of k-ras mutations in colorectal carcinomas
9. Genetic steps in colorectal cancer
10. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 mutations
11. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up
12. p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix
13. p53 accumulation in ovarian carcinomas and its prognostic implications
14. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas
15. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarcinomas
16. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma
17. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinicopathological parameters
18. The incidence of p53 mutations increases with progression of head and neck cancer
19. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model
20. Immunocytochemical detection of p53 in human gliomas
21. p53 protein immunostaining in routinely processed paraffin-embedded sections
22. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment
23. Implications of the p53 tumor-suppressor gene in clinical oncology
24. Sensitivity of detection of heterozygous point mutations in p53 cDNAs by direct PCR sequencing
25. Modulation of activity of the promoter of the human MDR1 gene by ras and p53
26. Thymocytes apoptotis induced by p53 dependent and independent pathways
27. A study of stabilization of p53 protein versus point mutation in colorectal carcinoma
28. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
29. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissues
30. Drug-target interactions: only the first step in commitment to programmed cell death?
31. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas
32. p53 protein and vimentin in invasive ductal NOS breast carcinoma. Relationship with survival and site of metastases
33. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer
34. Participation of p53 cellular tumor antigen in transformation of normal embryonic cells
35. The role and prognostic significance of p53 gene alterations in breast cancer
36. Efficacy of fluorescent-based PCR-SSCP for detection of point mutations
37. Accumulation of nuclear p53 and tumor progression in bladder cancer
38. A genetic model for colorectal tumorigenesis
39. Elevated P53 expression correlates with history of heavy smoking in squamous cell carcinoma of the head and neck
40. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with k-ras-2 mutation type
41. The p53 proto-oncogene can act as a supressor of transformation
42. p53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants?
43. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx
44. Gene therapy of cancer through restoration of tumor-suppressor function?
45. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
46. p53: from molecular mechanisms to prognosis in cancer (editorial)
47. High-risk human papillomavirus infections and over-expression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder
48. Prognostic significance of human papillomavirus genome (type-16,-18) and aberrant expression of p53 protein in human esophageal cancer
49. Relationship between immunocytochemically detectable p53 protein and prognostic factors in head and neck tumors
50. Tumor microvessel density, p53 expression, tumor size, and peritumoral vessel invasion are relevant prognostic markers in node-negative breast carcinoma
51. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis
52. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis
53. Association of p53 mutations with short survival in colorectal cancer
54. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival
55. Clinical implications of the p53 tumor-suppressor gene
56. Prognostic significance of p53 immunostaining in epithelial ovarian cancer
57. p53 gene mutations inside and outside of exons 5–8: the patterns differ in breast and other cancers
58. PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA
59. How sensitive is PCR-SSCP?
60. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation
61. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes
62. p53 mutations in human cancer
63. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer
64. Prognostic value of p53 protein expression in breast carcinomas
65. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis
66. Association of overexpression of tumor suppressor gene protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients
67. Prognostic significance of p53 overexpression in endometrial cancer
68. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer
69. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours
70. Cellular immortalization by cDNA clone encoding the transformation-associated phosphoprotein p53
71. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma
72. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes
73. Overexpression of p53 protein in betel- and tobacco-related human oral dysplasia and squamous-cell carcinoma in India
74. Clinical and pathologic associations with allelic loss in colorectal carcinomas
75. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry
76. Apoptosis. Its significance in cancer and cancer therapy
77. Human papillomavirus 16 E6 expression disrupts the p53-mediated response to DNA damage
78. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas
79. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
80. Expression of p53 in oligodendrogliomas
81. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection
82. T antigen is bound to a host protein in SV40-transformed cells
83. Inhibition of p53 DNA binding of human papillomavirus E6 proteins
84. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
85. The p53 tumour suppressor gene
86. Role of the p53 tumour-suppressor gene in tumorigenesis
87. Characterization of a 54K dalton cellular SV40 tumor antigen in SV40 transformed cells
88. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value
89. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis
90. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma
91. Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor supressor genes
92. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
93. p53 is required for radiation-induced apoptosis in mouse thymocytes
94. p53 status and the efficacy of cancer therapy in vivo
95. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer
96. p53 alterations in non-small cell lung cancer correlate with metastic involvement of hilar and mediastinal lymph nodes
97. Overexpression and mutation of p53 in epithelial ovarian cancer
98. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer
99. p53 expression and prognosis in gastric carcinoma
100. The relationship of p53 immunostaining to survival in carcinoma of the lung
101. Mutations of the p53 gene as a predcictor of poor prognosis in patients with non-small-cell lung cancer
102. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
103. Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms
104. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas
105. Relative efficiency of denaturing gel electrophoresis and single-strand conformation polymorphism in the detection of mutation in exon 5 to 8 of the p53 gene
106. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-stranded conformation polymorphism analysis of polymerase chain reaction products
107. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
108. Detection and localization of single base changes by denaturing gradient gel electrophoresis
109. Relationship among p53, stage, and prognosis of large bowel cancer
110. p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrial type. Ann immunohistochemical examination on paraffin sections
111. Mutations in the p53 gene occur in diverse human tumour type
112. A rapid and sensitive detection of point mutations and genetic polymorphisms using polymerase chain reaction
113. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study
114. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
115. Antibody for detecting p53 protein in immunohistochemistry in normal tissues
116. Immunochemical analysis of the interaction of p53 with MDM-2. Fine mapping of the MDM-2 binding site on p53 using synthetic peptides
117. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor
118. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer
119. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival
120. Increased p53 protein content of colorectal tumors correlates with poor survival
121. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis
122. Accumulation of wild type p53 protein in human astrocytomas
123. Distinct domains of p53 have a differential role in transcriptional activation and repression functions
124. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus
125. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression
126. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder
127. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study
128. p53 in colorectal cancer: clinicopathological correlations and prognostic significance
129. Induction of apoptosis by wild-type p53 in a human colon-derived cell line
130. Attachment of a 40-base-pair G+C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase reaction results in improved detection of single-base changes
131. p53 alteration in gastric precancerous lesions
132. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma
133. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis
134. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer
135. p53 as an independent prognostic marker in lymph node-negative breast cacer patients
136. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage
137. Prognostic significance of p53 overexpression in gastric and colorectal cancer
138. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma
139. Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity
140. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1
141. p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections
142. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers
143. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor
144. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma
145. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1−2M0 prostatic adenocarcinoma
146. p53 mutations have no additional prognostic value over stage in bladder cancer
147. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
148. Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast
149. p53 function and dysfunction
150. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis
151. Detecting base pair substitutions in DNA fragments by temperature-gradient gel electrophoresis
152. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis
153. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
154. Value of P-glycoprotein, glutathione-S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas
155. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients